CONTACTS
SUBJECTS
VA Prescribe Atorvastatin 10 MG Trial 4 Weeks Evaluate Side Effects In 48
6003 -
6003 - ..
6004 - Summary/Objective
6005 -
600501 - Follow up ref SDS 81 0000. ref SDS 70 0000.
600502 -
600503 - Productive meeting with VA team; Doctor Alba ordered additional lab to
600504 - check Chem Profile on elevated potassium that may cause electrical
600505 - problems for the heart, noted by Doctor Egan in Cardiology at VA
600506 - Clinic in Martinez. Potassium and other electrolytes were reported
600507 - high in Labcorp test, but are needed in VA system for efficient case
600508 - management. ref SDS 0 HY6O VA has done excellent work with plan of
600509 - care combining medication and physical activity to maintain favorable
600510 - lipid labs. ref SDS 0 X59G Physical activity with endurance exercise
600511 - hiking 300+ miles per month increased HDL 67 from 30, when CABG +4
600512 - surgery was performed 5 years ago in 2009. Equally, EPCs are likely
600513 - elevated, which causes regression of atherosclerosis, and which in
600514 - turn lowers CVD risk. ref SDS 0 T64J Orange juice was also increased
600515 - in line with studies showing positive effects increasing HDL.
600516 - ref SDS 0 4Z8I Coronary CTA with calcium score provides standard of
600517 - care testing response to treatment reducing atherosclerosis plaques to
600518 - evaluate level of care managing CVD risk. ref SDS 0 WS4L The medical
600519 - team worries patient anatomy changes from CABG surgery in 2009, makes
600520 - testing difficult with coronary CTA. ref SDS 0 J83H Research
600521 - indicates CTA radiology modalities are standard of care for testing
600522 - response to treatment after CABG surgery. ref SDS 0 OF7N Patient
600523 - history of elevated atherosclerosis was cited during the meeting.
600524 - There was concern testing severity of atherosclerosis after 5 years of
600525 - treatment will not add value to adjust treatment regardless of
600526 - results. ref SDS 0 M16K Reviewed standard of care for evidenced based
600527 - medical practice requires testing to measure severity of medical
600528 - problems that guides treatment. Coronary CTA with calcium score
600529 - yields results in time to make effective changes, ref SDS 0 6W3M
600530 - Patients need timely testing to avoid tragic outcomes illustrated by
600531 - Tim Russert case, where results came too late for survival.
600532 - ref SDS 0 NB7N Doctor Alba noted favorable labs indicate current
600533 - treatment is effective, so why test for regression of atherosclerosis?
600534 - ref SDS 0 467K Reviewed rising side effects of prescribed care.
600535 - ref SDS 0 PC8K The doctor referred urination side effects to Primary
600536 - Care for possible prostate issues arising from aging process.
600537 - ref SDS 0 EK4F Doctor Alba will add T Bili to make-up electrolytes
600538 - lab in order to evaluate rising peripheral neuropathy. ref SDS 0 P26G
600539 - The doctor will investigate referral to podiatry for relief of side
600540 - effects hiking 300 miles per month in order to maintain level of care
600541 - required for regression of atherosclerosis. ref SDS 0 YM5N Considered
600542 - reducing treatment to lower side effects. Since current care has been
600543 - effective there is reluctance to reduce treatment without evidence
600544 - atherosclerosis plaques have regressed that lower CVD risk. The
600545 - doctor advised that minor side effects must be tolerated in order to
600546 - benefit from lowering risks of atherosclerosis. Doctor Alba will
600547 - discuss with the VA team using coronary CTA with calcium score to test
600548 - for regression of atherosclerosis that will provide evidence that
600549 - supports reducing debilitating side effects by reducing treatment.
600550 - ref SDS 0 635O
600552 - ..
600553 - [On 140520 0732 letter to VA Medical Center in San
600554 - Francisco cites discussion on sore feet side effects of
600555 - hiking to lower CVD risk. ref SDS 97 UT5M
600557 - ..
600558 - [On 140520 0732 at 1017 VA lab Chem Profile shows
600559 - electrolytes generally improved - potassium (K) 5.2
600560 - declined from 5.6 on Labcorp test on 140508, and from 5.4
600561 - in VA lab on 140203 - additionally, glucose 98 declined
600562 - from 103, sodium 139 declined from 144, and T Bil 1.2
600563 - declined from 2.2. ref SDS 97 ZG5O
600565 - ..
600566 - [On 140529 0942 letter to VA requests progress ordering EPC
600567 - lab, and requests order for coronary CTA with calcium score
600568 - standard of care testing response to treatment for
600569 - regression of atherosclerosis. ref SDS A1 QG38
600571 - ..
600572 - [On 140612 1048 letter from Doctor Alba says VA refuses to
600573 - order EPC and CTA tests to evaluate regression of
600574 - atherosclerosis because CABG surgery on 091022, changed
600575 - anatomy which renders CTA test difficult, and since
600576 - customer has history of atherosclerosis the VA will not
600577 - test whether the problem has been resolved, declined,
600578 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
600579 - by Doctor Feingold as presented in Progress Notes for
600580 - meeting at VA on 140519 0800. ref SDS 0 OW49
600582 - ..
600583 - [On 140626 1652 letter notifies VA case studies show
600584 - failure to perform timely testing causes negative patient
600585 - outcomes. ref SDS A4 MY51 VA reference to patient having
600586 - vessel plaques 5 years ago, begs the question of testing to
600587 - determine how much plaque, and level of care required, if
600588 - any, to treat current condition. ref SDS A4 MZ33 Evidence
600589 - shows CTA common practice to evaluate atherosclerosis
600590 - post CABG surgery. ref SDS A4 MZ54
600592 - ..
600593 - [On 140929 1418 received letter from Doctor Alba to call VA
600594 - and schedule another meeting on managing lipids; called and
600595 - scheduled meeting with Doctor Rao, an attending physician,
600596 - on 141024 0830. ref SDS A8 8E5N
600598 - ..
600599 - [On 141022 1523 Doctor Rao called and changed the time of
600600 - the meeting from 0830 to 0900 on 141024. ref SDS B0 IF5M
600601 -
600602 -
600604 - ..
6007 -
6008 -
6009 - Background
6010 -
6011 -
601101 - Lab on 131015, showing cholesterol remained high, 131015 0724,
601102 - ref SDS 56 BE6O, conflict with increased exercise and weight loss,
601103 - discussed in the letter to the medical team yesterday on 131016 1632.
601104 - ref SDS 57 IW57
601106 - ..
601107 - On 131017 1000 VA medical chart Progress Notes assessment report
601108 - patient status CAD stable, asymptomatic. hyperlipidemia not
601109 - controlled. ref SDS 58 T24N
601111 - ..
601112 - On 131017 1000 Doctor Egan proposed referring patient for clinical
601113 - trial to reduce cholesterol with new "targeted" drugs. ref SDS 58 179N
601115 - ..
601116 - On 131017 1000 VA medical chart Progress Notes assessment report
601117 - patient status hyperlipidemia not controlled, ref SDS 58 PSXT; Doctor
601118 - Egan makes referral to SF VA Medical Center for consult on
601119 - participation clinical trials, ref SDS 58 EU9F, with experimental
601120 - agents such as AMGEN 145 and REGN 727 to resolve multiple statin
601121 - intolerance. ref SDS 58 CN4H
601123 - ..
601124 - On 131103 received letter from VA SF Medical Center scheduling meeting
601125 - on 131121 1000, to consider clinical trial for lowering cholesterol.
601126 - ref SDS 60 YT4N
601128 - ..
601129 - On 131112 New York Times published several articles reporting that the
601130 - day before on 131113, American Heart Association published new
601131 - guidelines for treating CAD patients that expand use of statin
601132 - medication regardless of cholesterol levels, ref SDS 61 0001, and
601133 - further raise the LDL 70 to LDL 190, as a target for cardiovascular
601134 - risk. ref SDS 61 CW6H
601136 - ..
601137 - On 131114 New York Times published several articles reporting that the
601138 - day before on 131113, American Heart Association published new
601139 - guidelines for treating CAD patients. ref SDS 62 SH6G
601141 - ..
601142 - On 131121 1604 meeting with Doctor Alba at San Francisco Medical
601143 - Center - prescribed Atorvastatin 20 mg 4-week trial and evaluate
601144 - adding Zetia 10 mg, schedule follow up on 131219 0930. ref SDS 63 6H6K
601146 - ..
601147 - On 131121 1604 in another record later today, VA prescription RX #
601148 - 5674471 for Atorvastatin 20 mg has been ordered. ref SDS 65 GH5M
601150 - ..
601151 - On 131125 0005 letter from Karen reports VA work plan to take statin
601152 - drug low dose Atorvastatin 10 mg for 4 weeks, then add Zetia 10 mg in
601153 - clinical trial for lowering cholesterol. ref SDS 67 V154
601155 - ..
601156 - On 131125 0005 research seems to indicate this clinical trial of low
601157 - dose Atorvastatin 10 mg with Zetia 10 mg has lowered cholesterol LDL
601158 - 70.
601160 - ..
601161 - On 131205 1448 received new prescription for Atorvastatin 20 mg,
601162 - ordered by Doctor Alba today for 4-week trial to assess side effects
601163 - for adding 2nd drug, Zetia 10 mg to lower LDL 249. ref SDS 68 GH5M
601165 - ..
601166 - On 131216 0028 letter to Doctor Alba submit agenda for meeting at VA
601167 - SFMC on 131219. ref SDS 69 HY6O
601169 - ..
601170 - On 131219 0930 meeting Doctor Alba at San Francisco VA Medical Center
601171 - ordered Ezetimibe 10 mg prescription for adding to Atorvastatin, and
601172 - ordered blood test to evaluate changes in lipid profile. 131219 0930,
601173 - ref SDS 70 NJ6G
601175 - ..
601176 - On 131230 1450, received Ezetimibe in US mail, ref SDS 71 5N3O,
601177 - ordered by Doctor Alba on 131219, 131219 0930, ref SDS 70 6H6K; begin
601178 - trial to manage cholesterol with Atorvastatin 10 mg and Ezetimibe 10
601179 - mg, planned during meeting at VA on 131121 0930. ref SDS 63 6H6K
601181 - ..
601182 - On 140114 0845 letter to Diana request Progress Notes meeting 131219,
601183 - ref SDS 72 HY6O, and ask about expanding scope pending lab to include
601184 - LDL-P. ref SDS 72 2140
601186 - ..
601187 - On 140115 1842 letter Diana will look for Progress Notes meeting
601188 - 131219, ref SDS 73 HY6O; investigating prospects for ordering lab test
601189 - LDL-P, ref SDS 73 CE80; VA claims patient cholesterol and LDL are above
601190 - target. ref SDS 73 CE91 VA further claims testing LDL-P not effective
601191 - in this case because LDL-C is not optimal. ref SDS 73 FF4H
601193 - ..
601194 - On 140116 0814 letter thanks Doctor Alba for investigating to find
601195 - Progress Notes for meeting at VA on 131219. ref SDS 74 HY6O Cite
601196 - research indicating patient with discordant LDL-C high and LDL-P low,
601197 - shown in patient lab on 131015, constitutes least risk for
601198 - arteriolosclerosis disorder, CVD, myocardial infarction. ref SDS 74 735Y
601200 - ..
601201 - On 140128 1327 letter asks again about Progress Notes meeting 131219,
601202 - ref SDS 75 HY6O; report hiking 11 miles per day continued, weight hit
601203 - 165, ref SDS 75 TZ8U; ask where to get lab at VA Martinez, in San
601204 - Francisco, or at UCSF. ref SDS 75 TZ96 No side effects from
601205 - Atorvastatin and Ezetimibe. ref SDS 75 TZ99
601207 - ..
601208 - On 140131 0815 have not received instructions from VA on getting lab
601209 - to test LDL-P, so ordered test. ref SDS 76 OO5G lab blood draw at
601210 - Labcorp in Walnut Creek on Ygnacio Valley Road. ref SDS 76 NT6T
601212 - ..
601213 - On 140201 1159 obtained blood draw for Lipid NMR test at Labcorp on
601214 - Health Testing Centers order # 27716, ref SDS 77 KQ4L, showing
601215 - "concordance" LDL-P 861, LDL-C 81, HDL 61, TG 68, LDL (pattern A) size
601216 - = large buoyant protective. ref SDS 77 IM9N
601218 - ..
601219 - On 140203 1147 VA blood draw at Martinez clinic to cross check Labcorp
601220 - blood test. 140203 1147, ref SDS 78 KK9M, showing LDL-C 93, HDL 58, TG
601221 - 47, ref SDS 78 IM9N, indicating "concordance" LDL-P 626, LDL (pattern
601222 - A) size = large buoyant protective. ref SDS 78 QV5G
601224 - ..
601225 - On 140204 1236 letter from VA today, notifies that Progress Notes for
601226 - meeting on 131219, have been posted and are available for customer to
601227 - receive from ROI department. ref SDS 79 HY6O Cause for 6-weeks delay
601228 - issuing Progress Notes not clear in the record. ref SDS 79 V44F VA
601229 - Progress Notes for meeting on 131219, are comprehensive and helpful.
601230 - ref SDS 79 MR3G Progress Notes have many minor grammatical errors
601231 - likely due to limited time, ref SDS 79 MZ5H, VA does not support NMR
601232 - lipid tests to determine LDL-P and discordance with LDL-C; patient can
601233 - obtain test from another lab. ref SDS 79 CE80 VA letter today
601234 - maintains discordance with low LDL-P and high LDL-C is "unhealthy" -
601235 - submits no evidence from medical literature supporting this
601236 - proposition, nor to address literature submitted to the VA stating
601237 - discordance is the healthiest condition for CVD patients. ref SDS 79
601238 - 6U4L VA concurs that lowering weight toward BMI standards aids
601239 - resolving hyperlipidemia. ref SDS 79 8N9H VA maintains lifestyle
601240 - through exercise and diet to control weight and hyperlipidemia require
601241 - support taking statin medications, e.g., Atorvastatin and Ezetimibe.
601242 - ref SDS 79 GT5F VA letter today says patient mis-reads literature on
601243 - discordance between LDL-P and LDL-C, and proposes discussions to
601244 - clarify this matter during meeting scheduled on 140213. ref SDS 79 HU5M
601245 - VA prefers patient get labs drawn at San Francisco VA Medical Center.
601246 - ref SDS 79 PT3M
601248 - ..
601249 - On 140211 0133 letter submits agenda to VA for meeting scheduled on
601250 - 140213. ref SDS 80 HY6O Progress Notes on 131219 received from VA on
601251 - 140204 1236. ref SDS 79 HY6O, stating LDL-P provides stronger
601252 - association with CVD risk, ref SDS 70 GO35, and VA letter saying
601253 - patient can support the team with NMR lab, reported on 140204 1236.
601254 - ref SDS 79 CE80, was implemented on February 1 using Labcorp. VA
601255 - request to have lab at San Francisco reported on 140204 1236.
601256 - ref SDS 79 PT3M, was received the day after lab was drawn at Martinez.
601257 - Will do VA labs in San Francisco for next cycle. ref SDS 80 TU68
601259 - ..
601260 - On 140211 0133 letter notifies VA consolidated patient history shows
601261 - strong alignment, ref SDS 80 TV31, between NMR test on 140201, and VA
601262 - lipid panel 2 days later on 140203. ref SDS 78 IM9N Low LDL-P 861
601263 - concordant with low LDL-C 81 in Labcorp NMR report on 140201. TG 47
601264 - and HDL 58 in VA lab 2 days later on 140203 1147, ref SDS 78 5C7M,
601265 - aligns with Labcorp results. ref SDS 80 TV3M Labcorp further shows
601266 - LDL size 21.3 is "pattern A", indicating large, buoyant LDL particles
601267 - "protect" against CVD. While research indicates discordance with
601268 - LDL-P low and LDL-C high is the healthiest cardiovascular condition
601269 - shown on 131125 0005, ref SDS 67 FI3G, and submitted to the VA in a
601270 - letter on 140116 0814, ref SDS 74 H29T; and previously cited in a
601271 - prior letter on 140114 0845, ref SDS 72 2140, patient healthy and very
601272 - grateful for outstanding care by entire VA team. ref SDS 80 TV3M
601274 - ..
601275 - On 140211 0133 letter notifies VA lab on 140203 improving prior lab on
601276 - 131015, ref SDS 80 TV40, resulted from Atorvastatin 40 mg - 4 weeks
601277 - beginning on 131121, shown in case study on 120101 0900, ref SDS 29
601278 - RN3F, then Atorvastatin 10 mg and Ezetimibe 10 mg beginning on 131230,
601279 - also in case study, ref SDS 29 6A6H, making total for 8 weeks
601280 - Atorvastatin 1850 mg, Ezetimibe 340 mg; as well, hiking 933 miles,
601281 - weight loss to 165, low-carb diet, chia seeds, orange juice, as
601282 - further set out in the record for the lab at the VA on 140203.
601283 - ref SDS 78 I17G
601285 - ..
601286 - On 140211 0133 letter notifies VA lab on 140203 shows potassium (K 5.4)
601287 - is elevated again, ref SDS 80 TV5F, and T Bilirubin 2.1 further
601288 - increased again, while Labcorp shows these are stable. ref SDS 78 ZG5O
601290 - ..
601291 - On 140213 0830 meeting at VA Medical Center in San Francisco
601292 - ref SDS 81 195I, good progress lowering risks of CVD based on
601293 - concordant low LDL-P 861 with low LDL-C 81. shown by lab NMR lipid
601294 - panel. ref SDS 81 TB6J Medical team excellent results collaborating
601295 - doctor/patient partnership. ref SDS 81 1L7M Atorvastatin 40 mg
601296 - started 131121, and then changed to Atorvastatin 10 mg with Ezetimibe
601297 - 10 mg started 131230. ref SDS 81 IE7F No side effects taking
601298 - medication. ref SDS 81 333L Discordance between LDL-P and LDL-C
601299 - discussed. ref SDS 81 WM8J Continue medication, diet, exercise and
601300 - weight loss protocols, and test lipid panel again in 3 months on
601301 - 140519 0800. ref SDS 81 8X5O
601303 - ..
601304 - On 140213 0830 meeting at VA Medical Center in San Francisco request
601305 - test for regression of atherosclerosis plaque using coronary CTA to
601306 - evaluate CVD risk which 5 years earlier required surgery in 2009.
601307 - ref SDS 81 JZ4O
601309 - ..
601310 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601311 - Francisco have numerous errors, e.g., failing to report hiking 933
601312 - miles that lowered Triglycerides and raised HDL to reduce CVD risk
601313 - through regression of atherosclerosis. ref SDS 81 O55H VA
601314 - representation that LDL "still not at goal" conflicts with the record,
601315 - and fails to present the "goal" and the authority that supports it.
601316 - ref SDS 81 WF5J VA representation that total cholesterol and LDL-C
601317 - are above target conflicts with the most recent lab showing both labs
601318 - are below target. ref SDS 81 5I7H
601320 - ..
601321 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601322 - Francisco state LDL-P has stronger association with cardiovascular
601323 - risk than LDL-C. ref SDS 81 S35H Patient LDL-P 861 with Labcorp test
601324 - on 140201, is "optimal" - 150 points lower target of 1000 for minimal
601325 - CVD risk, shown in consolidated lab on 140203. ref SDS 78 BE6O VA
601326 - representation that patient LDL-C is not at optimal levels conflicts
601327 - with VA record of lab tests on 140203 1147, ref SDS 78 BE6O, and is
601328 - otherwise not supported by reference to recognized authority.
601329 - ref SDS 81 S35H
601331 - ..
601332 - On 140213 0830 Progress Notes for meeting at VA Medical Center in San
601333 - Francisco Plan of care prescribes continue physical activity and low
601334 - fat/low cholesterol diet. ref SDS 81 E34O
601336 - ..
601337 - On 140226 1332 letter to VA transmits notes of meeting on 140213.
601338 - ref SDS 82 HY6O Report cold symptoms side effects taking Atorvastatin
601339 - with Ezetimibe. ref SDS 82 JY8K Request coronary CTA radiology test
601340 - regression atherosclerosis. ref SDS 82 JR99 Request Progress Notes
601341 - meeting on 140213. ref SDS 82 JY4M
601343 - ..
601344 - On 140303 1644 letter to VA reports recovery from symptoms of cold,
601345 - which may indicate this was not caused by prescribed medication side
601346 - effects taking Atorvastatin and Ezetimibe. ref SDS 83 HY6O Letter
601347 - requests Progress Notes for meeting a few weeks ago at Medical Center
601348 - in San Francisco, and because Release of Information (ROI) department
601349 - at the VA Clinic in Martinez has been delayed issuing patient medical
601350 - records. ref SDS 83 E788
601352 - ..
601353 - On 140305 1117 letter to VA follows up asking about work plan in
601354 - Progress Notes doing CT and other testing to evaluate regression of
601355 - atherosclerosis, ref SDS 84 WY3X, since CABG x4 surgery on 091022
601356 - 0700. ref SDS 15 PQWU
601358 - ..
601359 - On 140307 1509 letter notifies VA that Ezetimibe and Atorvastatin
601360 - prescription refill not delivered, and so treatment is paused pending
601361 - delivery. 140307 1509, ref SDS 85 5N3O
601363 - ..
601364 - On 140307 1509 at 1730 VA letter reports plans to investigate to
601365 - resolve delayed delivery of prescription refill for Atorvastatin and
601366 - Ezetimibe. ref SDS 85 MS9N
601368 - ..
601369 - On 140308 0956 another letter asking VA to investigate delayed
601370 - delivery medication refills. ref SDS 86 II91
601372 - ..
601373 - On 140310 0939 another letter to VA requests assistance again
601374 - resolving delayed delivery medication refills for Atorvastatin and
601375 - Ezetimibe. ref SDS 87 LS88 On 140310 0939 at 1121 VA letter responds
601376 - to letter sent at 0939, and asks if medication refills have been
601377 - delivered for Atorvastatin and Ezetimibe. ref SDS 87 VP4J At 1156
601378 - notified VA have not received medication. ref SDS 87 345R
601380 - ..
601381 - On 140311 1730 received prescription refill for Atorvastatin and
601382 - Ezetimibe, delivered by neighbor because mailman delivered to the
601383 - wrong mailbox; treatment resumed. ref SDS 88 YS4O At 1903 notified VA
601384 - medication refill was received, so treatment resumed. ref SDS 88 KF5I
601386 - ..
601387 - On 140312 1720 letter to VA Medical Center in San Francisco submits
601388 - comments on Progress Notes for meeting on 140213. ref SDS 89 5N3O
601389 - Recommend corrections to avoid propagating errors forward when current
601390 - Progress Notes are used to expedite making Progress Notes for the next
601391 - meeting scheduled on 140519. ref SDS 89 IL83
601393 - ..
601394 - On 140312 1720 letter to VA Medical Center in San Francisco submits
601395 - question on goals for HDL and TG to lower LDL-P that has the strongest
601396 - association with CVD risk, ref SDS 89 IL4M, cited in VA Progress Notes
601397 - on 131219, ref SDS 70 GO35, and restated in Progress Notes for meeting
601398 - on 140213 0830. ref SDS 81 S35H
601400 - ..
601401 - On 140312 1720 letter to VA Medical Center in San Francisco requests
601402 - guidance in Progress Notes on goals for diet and exercise that yielded
601403 - dramatic rise in HDL 21% and reduction of TG 60%, given that research
601404 - indicates Atorvastatin and Ezetimibe have been found to increase HDL
601405 - 5%-9%, and lower TG 30%-40% [...reported on 131125 0005. ref SDS 67
601406 - PU6I...] - see AHA article Circulation published 030428...
601408 - ..
601409 - On 140312 1720 letter to VA Medical Center in San Francisco requests
601410 - testing for regression of atherosclerosis that lowers CVD risk based
601411 - on labs showing elevated HDL in combination with low TG, ref SDS 89
601412 - PSXX, discussed during the meeting on 140213 0830, ref SDS 81 JZ4O,
601413 - citing research on 131125 0005. ref SDS 67 E13K.
601415 - ..
601416 - On 140430 0900 at 0400 letter to Doctor Egan Cardiology VA Clinic
601417 - Martinez agenda for meeting 0900, ref SDS 91 HY6O, report patient
601418 - history of lipid labs, ref SDS 91 PT53, may show discordance with
601419 - LDL-P low and LDL-C high, indicating low risk CVD. ref SDS 91 PT6N
601421 - ..
601422 - On 140430 0900 at 0400 letter to Doctor Egan Cardiology VA Clinic
601423 - Martinez agenda meeting at 0900 reported maintained training protocol
601424 - hiking 11 miles daily, along with low-carb diet training for hiking
601425 - Half Dome on 140917. Weight has reached 164, as shown in patient
601426 - history, but is most often about 170 after hiking. ref SDS 91 PU34
601428 - ..
601429 - On 140430 0900 at 0900 meeting Doctor Egan Cardiology VA Clinic
601430 - Martinez discussed CTA imaging tests to assess regression of
601431 - atherosclerosis plaque, ref SDS 91 2F6O, that required CABG +4 on
601432 - 091022 0700, ref SDS 15 PQWU, as considered previously with the VA
601433 - during the meeting in San Francisco on 140213 0830, ref SDS 81 JZ4O,
601434 - and cited in the letter on 140312 1720. ref SDS 89 PSXX Doctor Egan
601435 - seemed to indicate that patient history of CABG +4 surgery 5 years ago
601436 - on 091022, makes evaluating regression of atherosclerosis unnecessary
601437 - to adjust prescribed care of medication and extended exercise for the
601438 - purpose of saving and money, and reducing painful side effects.
601439 - ref SDS 91 OK7L
601441 - ..
601442 - On 140430 0900 meeting Doctor Egan Cardiology VA Clinic Martinez
601443 - reported hiking stresses left knee injured in a fall of 40' back in
601444 - 1973, causing degenerative arthritis. In past month or so, feet have
601445 - begun to hurt, so it remains a challenge to control CVD risk through
601446 - exercise. Glucosamine Chondroitin helps resolve some of this problem,
601447 - with the result that hiking this year is about 300 miles ahead of the
601448 - record hiking through the 1st 4 months of last year. ref SDS 91 PU37
601449 - Doctor Egan encouraged extended endurance hiking for lowering LDL
601450 - cholesterol and triglycerides and raising HDL that reduce CVD risk.
601451 - ref SDS 91 RI9N The doctor asked about resting heart rate,
601452 - ref SDS 91 297N, this has reduced to below 60, due to increased
601453 - endurance hiking, shown from patient history beginning on 140422,
601454 - shown in case study on 120101 0900. ref SDS 29 RQ6H
601456 - ..
601457 - On 140430 0900 meeting Doctor Egan Cardiology VA Clinic Martinez
601458 - reported slight and occasional dizziness when laying down and turning
601459 - my head. ref SDS 91 PU43 Overall health very good. CT study on
601460 - 130117 showed esophagus has finally returned to normal, without the
601461 - big bubble that was there for 5 years or so. Accordingly, VA has
601462 - provided outstanding health care. ref SDS 91 PU47
601464 - ..
601465 - On 140430 0900 letter from Doctor Egan, Cardiology Physician at
601466 - Martinez Clinic, notes medical team did not address elevated potassium
601467 - in labs, and again notifies that this condition represents exposure to
601468 - "electrical problems" with the heart. ref SDS 91 UV5I
601470 - ..
601471 - On 140505 0936 Doctor Egan notified that medical team at VA Medical
601472 - Center in San Francisco was advised of concerns on elevated potassium
601473 - (K) and Total Bilirubin, ref SDS 92 YV4L, shown in labs reported in
601474 - the record on 140203 1147. ref SDS 78 ZG5O
601476 - ..
601477 - On 140508 1133 lab for VA from Labcorp at John Muir Clinic shows
601478 - glucose, sodium at high end of range, and shows potassium and T bili
601479 - above range, ref SDS 93 WJ5H, indicating influence of extended
601480 - endurance hiking 22 miles the day before, and another 11 miles morning
601481 - of the blood draw, and possibly caused by statin and ezetimibe
601482 - treatment to lower LDL cholesterol, as discussed in Notes of the lab
601483 - on 140508 1133. ref SDS 93 G34G Lipid panel shows further improvement
601484 - with LDL-P 851 down 10 points and HDL 67 up 6 points from 4 months
601485 - earlier. ref SDS 93 BE6O Improved lipid history, ref SDS 93 W25L,
601486 - reveres prior history of worsening lipids occurring after significant
601487 - improvement, and is attributed to increased endurance hiking 300 miles
601488 - per month and adding orange juice at approximately 500 ml per day.
601489 - ref SDS 93 I17G
601491 - ..
601492 - On 140514 0950 lab at VA Medical Center in San Francisco to support
601493 - meeting with Doctor Alba on 140519. ref SDS 94 X45G Excellent lipid
601494 - lab, ref SDS 94 IM9N, aligns with Labcorp blood test using NMR
601495 - technology last week on 140508 1133. ref SDS 93 5C7M Reflects
601496 - increased hiking and weight control past 3.5 months, reported in case
601497 - study on 120101 0900, ref SDS 29 PYXR, and supported with low carb
601498 - diet (including orange juice) and low dose medication, reported on
601499 - 140513, in the same study. ref SDS 29 ZU5G Favorable results seemed
601500 - "too good to be true" and so the VA lab did a second test to
601501 - corroborate findings shown by (a) and (b) scores. ref SDS 94 5C7M
601503 - ..
601504 - On 140515 2043 letter to VA submits consolidated results of Labcorp
601505 - test on 140508 with VA test on 140514, noting continued favorable
601506 - lipid panel improves patient history past 3 years of worsening results
601507 - after significant improvement. ref SDS 95 1V6M
601509 - ..
601510 - On 140515 2043 letter to VA submits reports meeting with Doctor Egan
601511 - in Cardiology at Martinez Clinic on 140430. ref SDS 95 YM67 After the
601512 - meeting, the doctor wrote a letter noting again that potassium (K) was
601513 - elevated in lab on 140203, and cited risk of "electrical problems" for
601514 - CAD patients (see line 392120. ref SDS 91 UV5I
601516 - ..
601517 - On 140515 2043 letter to VA reports that on 140513, weight dropped to
601518 - 163, lowest in 30 years, after hiking another 1000 miles since prior
601519 - labs in February, ref SDS 95 YM82, see case study (see line 105253
601520 - shown on 120101 0900. ref SDS 29 PYXR
601522 - ..
601523 - On 140515 2043 letter to VA reports medication side effects slight
601524 - dizziness in past month when laying down and turning my head left or
601525 - right. There may also be increased urination the past month or so,
601526 - but this is hard to track. Seem to be getting up a lot during the
601527 - night, as occurred with Rosuvastatin, but could be imagination - not
601528 - sure yet. ref SDS 95 YM98
601530 - ..
601531 - On 140515 2043 letter to VA requests coronary CTA with calcium score
601532 - to evaluate regression of atherosclerosis. ref SDS 95 YM41 Further
601533 - requests EPC lab to assess favorable conditions along with elevated
601534 - HDL for regression of atherosclerosis. ref SDS 95 YM61
601536 - ..
601537 - On 140515 2043 letter to VA reports labs show excellent care at the VA
601538 - achieving favorable results lowering CVD risk for continuing cycles.
601539 - As noted initially, in past years, whenever HDL increased and
601540 - Triglycerides dropped, on the next test the numbers got worse, see
601541 - patient Lipid History Trend Analysis on 140508 (line 610726.
601542 - ref SDS 94 W25L Thanks to skill and persistence of the VA medical
601543 - team, this time the numbers improved. ref SDS 95 YM64
601545 - ..
601546 - On 140518 2120 letter submits agenda to Doctor Alba for meeting
601547 - tomorrow on 140519, at VA Medical Center in San Francisco. ref SDS 96
601548 - 1V6M Medication side effects of dizziness seems to have subsided.
601549 - ref SDS 96 DV50 Very dry mouth in the night past week, and frequency
601550 - of urination has further increased, indicating dehydration issue,
601551 - possibly associated with elevated bilirubin. ref SDS 96 DV56
601552 - Peripheral neuropathy has returned, possibly related to bilirubin.
601553 - Follows prior pattern with Rosuvastatin, but at this time the problem
601554 - is very minor, only a few occasions the past 2 weeks or so.
601555 - ref SDS 96 DV59
601556 -
601557 -
601558 -
601559 -
601561 - ..
6016 -
6017 -
6018 - Progress
6019 -
6020 -
602001 - Lab Electrolytes Cross Check Potassium T Bili Doctor Egan Request
602002 - Potassium T Bili Lab Cross Check Electrolytes Request Doctor Egan
602003 -
602004 - Follow up ref SDS 96 DV4M, ref SDS 95 YM7H.
602005 -
602006 - Doctor Alba advised there wasn't enough time to read the letter to the
602007 - VA on 140515, ref SDS 95 YM7H, reporting Doctor Egan's request in a
602008 - letter on 140430, for follow up lab to re-check electrolyte panel,
602009 - ref SDS 91 UV5I, with primary concern about elevated potassium that
602010 - can cause electrical problems with the heart. ref SDS 91 UV5Y As a
602011 - result of a hectic schedule preventing timely review of the record,
602012 - the doctor's letter yesterday on 140518, notified that the VA decided
602013 - not to do an electrolyte lab, ref SDS 96 RW7O, responding to patient
602014 - letter also yesterday on 140518, ref SDS 96 DV4M, asking again about
602015 - following up on Doctor Egan's request on 140430, for a Chem Profile
602016 - (electrolytes) lab. ref SDS 91 UV5Y
602017 -
602018 - [On 140929 1418 received letter from Doctor Alba to call VA
602019 - and schedule another meeting on managing lipids; called and
602020 - scheduled meeting with Doctor Rao, an attending physician,
602021 - on 141024 0830. ref SDS A8 8E5N
602023 - ..
602024 - [On 141022 1523 Doctor Rao called and changed the time of
602025 - the meeting from 0830 to 0900 on 141024. ref SDS B0 IF5M
602027 - ..
602028 - This morning during the meeting we reviewed the record presented in
602029 - the letter on 140515 2043. ref SDS 95 1V6M
602031 - ..
602032 - Doctor Alba was pleased that Labcorp included electrolytes in the
602033 - recent lab on 140508. She indicated Labcorp results appear skewed by
602034 - patient physical activity hiking 22 miles the day before and another
602035 - 11 miles in the morning before the blood draw, reported in the letter
602036 - to the VA on 140515 2043, ref SDS 95 YM79, possibly causing Labcorp
602037 - test for potassium (K) 5.6 to actually increase from 5.4 even farther
602038 - above the range of 4.8 in prior VA lab on 140203, ref SDS 93 ZG5O, and
602039 - which was the cause of Doctor Egan's concern in the letter on 140430.
602040 - Doctor Alba also indicated that case management is faster and easier
602041 - for comprehensive care when patient history can be accessed directly
602042 - on the VA computer system, rather than rely on results from outside
602043 - labs, like Labcorp.
602045 - ..
602046 - As a result, she wants the patient to avoid physical exercise, in
602047 - particular stand down on 11 mile daily hikes until after the next lab.
602048 - She will order a Chem Profile (electrolytes) lab to check skewed
602049 - results for glucose, sodium, potassium and T Bilirubin in the Labcorp
602050 - lab on 140508, as shown with results for VA lab on 140514, which for
602051 - some reason omitted the electrolytes (Chem Profile panel). ref SDS 94
602052 - KK9M
602054 - ..
602055 - [On 140520 0732 letter to Doctor Alba requesting notice
602056 - that order has been placed for follow up lab for
602057 - electrolytes at the VA Medical Center prior to driving into
602058 - San Francisco. ref SDS 97 YW4H
602060 - ..
602061 - [On 140520 0732 at 0812 letter from Doctor Alba notifying
602062 - that order for electrolytes lab will be issued OA 0845.
602063 - ref SDS 97 4V5H
602065 - ..
602066 - [On 140520 0732 at 1017 VA lab Chem Profile shows
602067 - electrolytes generally improved - potassium (K) 5.2
602068 - declined from 5.6 on Labcorp test on 140508, and from 5.4
602069 - in VA lab on 140203 - additionally, glucose 98 declined
602070 - from 103, sodium 139 declined from 144, and T Bil 1.2
602071 - declined from 2.2. ref SDS 97 ZG5O
602072 -
602073 -
602075 - ..
602076 - VA Success Managing Cholesterol for Regression Atherosclerosis
602077 - Hyperlipidemia Cholesterol Controlled Exercise Diet Medication
602078 - Cholesterol Managed Clinical Trial Exercise Diet Medication
602079 - Clinical Trial Considered Lower Cholesterol Without Statin Drugs
602080 -
602081 - Follow up ref SDS 81 HY6O, ref SDS 70 HY6O.
602082 -
602083 - Doctor Alba very pleased LDL-P 851 dropped well below the target of
602084 - 1000 for good cholesterol health, indicating effective lipid
602085 - management for cardiovascular health. Equally critical HDL 67
602086 - increased again, and together with triglycerides (TG) 58 yield TG/HDL
602087 - ratio 0.88 that enables rapid regression of atherosclerosis, shown in
602088 - the record consolidating Labcorp test on 140508 with VA lab yesterday
602089 - on 140514 0950. ref SDS 94 IM9N
602091 - ..
602092 - During the prior meeting on 140213 0830, reviewed Doctor Alba's report
602093 - that LDL-P has the strongest association with CVD risk. ref SDS 81
602094 - UV4O This was confirmed in VA Progress Notes for meeting on 140213.
602095 - ref SDS 81 S35H At that time on 140213, reviewed research with the
602096 - doctor indicating lowest risk for CVD is low LDL-P and high LDL-C,
602097 - and; concomitantly the highest risk is high LDL-P and low LDL-C.
602098 - ref SDS 81 UV4O Doctor Alba's Progress Notes for the prior meeting
602099 - mention reviewing this research, but do not present the actual
602100 - findings. ref SDS 81 I35L
602102 - ..
602103 - Today, the doctor further noted the VA lab on 140514, found LDL-C 87
602104 - remains well below VA published goal LDL-C <= 131. ref SDS 94 5C7M
602105 - LDL-C 87 is more than 50% lower than current AHA guidelines for LDL-C
602106 - < 190, reported on 131112 1422. ref SDS 61 HT87
602108 - ..
602109 - Doctor Alba appreciated attribution in the letter on 140515,
602110 - commending the VA medical team for maintaining excellent lipid labs
602111 - over 2 cycles, ref SDS 95 YM64, which has not previously occurred in
602112 - patient history the past 8 years, beginning in 2006, shown in the
602113 - record of Patient Lipid History on 140514. ref SDS 93 W25L
602114 -
602115 -
602117 - ..
602118 - Physical Activity Hike 300 Miles Per Month Prescription Lower CVD Risk
602119 - Weight Lowest 30 Years Prescribed Low Carb Diet and Physical Activity
602120 - Prescribed Care Implemented Rigorously through Doctor Patient Collaboration
602121 -
602122 - Doctor Alba commended dropping weight to 163, lowest in 30 years,
602123 - after hiking 2 laps (22 miles) on 140513, reported in case study of
602124 - patient history on 120101 0900, ref SDS 29 ZU5G She credited
602125 - compliance with low carb diet and continuing physical activity
602126 - prescribed in Progress Notes on 140213 0830, ref SDS 81 MQ5G, for
602127 - reducing weight from 200 last year to 165 or even 160, which she
602128 - presented during a prior meeting at the VA on 131219, 0930.
602129 - ref SDS 70 A56N
602131 - ..
602132 - Favorable patient outcome reflects effective doctor patient
602133 - partnership through strong communications, illustrated by the letter
602134 - submitted on 140515, requesting coronary CTA with calcium score to
602135 - test response to treatment for regression of atherosclerosis.
602136 - ref SDS 95 YM41 Effective doctor patient collaboration at the VA
602137 - aligns with standard of care for evidence based medical practice, set
602138 - out in a letter to UCSF and Kaiser on 090725 2017. ref SDS 11 T55T
602140 - ..
602141 - Prescribed treatment to continue physical activity was implemented
602142 - hiking 11 miles per day and averaging 300 miles per month shown in
602143 - patient history on daily medication, diet, vitals and exercise, listed
602144 - in case study on 120101 0900. ref SDS 29 QJ5I
602146 - ..
602147 - Mileage 2014 Miles Minutes
602148 -
602149 - 131103....Oct................. 373 5757 ...... ref SDS 29 6F9N
602150 - 131201....Nov................. 172 2899 ...... ref SDS 29 XRPV
602151 - 131229....Dec................. 234 3324 ...... ref SDS 29 XXQY
602152 - 140202....Jan................. 347 5393 ...... ref SDS 29 YWST
602153 - 140302....Feb................. 234 3681 ...... ref SDS 29 PYWS
602154 - 140330....Mar................. 207 3313 ...... ref SDS 29 RXPR
602155 - 140427....Apr................. 310 4402 ...... ref SDS 29 RXVV
602156 - 140601....May...projected..... 322 5338 ...... ref SDS 29 SXWV
602158 - ..
602159 - This level of endurance exercise aids weight control and lowers
602160 - triglycerides, shown in research on 131125, ref SDS 66 U44L, which was
602161 - submitted to the VA in the letter on 140515. ref SDS 95 YM82
602162 -
602163 - [...below on 140519 0800 Doctor Alba noted that elevated T
602164 - Bilirubin that may drive or compound peripheral neuropathy
602165 - side effects of statin drugs, can also be caused by
602166 - vigorous exercise prescribed for continuing physical
602167 - activity to lower CVD risk. ref SDS 0 U56J
602168 -
602170 - ..
602171 - HDL 67 Increased with Sufficcient Exercise Training
602172 - Orange Juice Clinical Trial Increases 21% with Sufficient Quantity
602173 -
602174 - The same study reviewed on 131125, noted: "It is now fairly well
602175 - recognized that endurance exercise training can increase plasma HDL
602176 - cholesterol levels, if the exercise training stimulus is sufficient.
602177 - Furthermore, several studies have suggested that HDL-raising effect of
602178 - endurance exercise training could be largely explained by the
602179 - concomitant loss of body mass or fat." ref SDS 66 6R7O
602181 - ..
602182 - Patient lipid history shows HDL increased from 30 to 67 following CABG
602183 - +4 cardiothroacic surgery on 091022, reported in case study on 140514
602184 - 0950. ref SDS 94 W25L
602186 - ..
602187 - Orange juice was also discussed during the meeting today, for
602188 - contributing to 30% rise from HDL 50 on 131015, to HDL 67 on 140514,
602189 - shown in patient history on lipid labs in the record on 140514 0950.
602190 - ref SDS 94 W25L Doctor Alba feels this correlates with the study
602191 - reviewed on 131125 0005, ref SDS 66 K34L, and submitted to the VA in
602192 - the letter on 140515 2043, ref SDS 95 YM5N, also presented in the
602193 - record reviewing favorable HDL lab results on 140514 0950. ref SDS 94
602194 - LO4J
602196 - ..
602197 - [...below on 140519 0800 VA Progress Notes report patient
602198 - increased intake of orange juice; needs to show quantity of
602199 - juice consumed in relation to rise in HDL aligns with
602200 - published studies reporting favorable correlation.
602201 - ref SDS 0 PB4I
602203 - ..
602204 - In this case, drinking orange juice 1 gallon (3786 ML) per week (541
602205 - ML/day) added to diet on 131125, based on study indicating HDL
602206 - increased 21% over 4 weeks with 750 ml per day (i.e., 1.4 gal per
602207 - week), ref SDS 67 R48K, as reported to VA in letter on 140114 0845.
602208 - ref SDS 72 218O Some research also indicates grape juice increases
602209 - HDL; however, no studies have quantified this effect. Patient
602210 - actually drinks combination of lemon juice, orange juice, and grape
602211 - juice in large quantities to hydrate after hiking 11 miles per day.
602213 - ..
602214 - HDL 67 increase from HDL 50 = 34% rise in 6 months from Dec 2013 - May
602215 - 2014, shown in patient history on 140514. ref SDS 94 W25L, represents
602216 - approximately 7% for each 4 week period. It may reflect drinking 541
602217 - ML of orange juice rather than 750 ML per day used in the study.
602218 - Raising HDL consistently 7% over 4 weeks for 6 months taking only 541
602219 - ML in this case, presents improved results compared to study results
602220 - finding 500 ML of orange juice for 4 weeks had no effect on HDL
602221 - levels. Improved results in this case may indicate orange juice at
602222 - 540 ML/day combined with hiking 11 miles per day, discussed below,
602223 - provides a direct path to improve lipid profiles toward avoiding and
602224 - regressing atherosclerosis plaque.
602225 -
602226 -
602228 - ..
602229 - Atherosclerosis Regresses Rapidly With Elevated HDL and EPCs
602230 -
602231 - Follow up ref SDS 81 JZ4O.
602232 -
602233 - Research on 131125, further found that elevated HDL cholesterol
602234 - produced in the liver, together with circulating endothelial
602235 - progenitor cells (EPCs) produced in the bone marrow, both driven by
602236 - extended endurance exercise (e.g., running, hiking, biking, swimming),
602237 - ref SDS 66 6O9M, are pathophysiological conditions for rapid
602238 - regression of atherosclerotic plaques, ref SDS 66 HG90, thus lowering
602239 - CVD risk.
602240 -
602241 - [On 140520 0732 letter next day to VA requests adding EPCs
602242 - to make-up lab, ref SDS 98 4U46, ordered by Doctor Alba for
602243 - adding electrolytes to check for elevated potassium, per
602244 - discussion today above. ref SDS 0 VO4F
602246 - ..
602247 - Coronary CTA with calcium score provides standard of care testing
602248 - response to treatment reducing atherosclerosis plaques to evaluate CVD
602249 - risk, presented in the letter to the VA on 140515 2043, ref SDS 95
602250 - YM41, following up discussion during the prior meeting on 140213 0830.
602251 - ref SDS 81 JZ4O
602252 -
602253 - [On 140529 0942 letter to VA requests progress ordering EPC
602254 - lab, and requests order for coronary CTA with calcium score
602255 - standard of care testing response to treatment for
602256 - regression of atherosclerosis. ref SDS A1 QG38
602258 - ..
602259 - Doctor Alba noted advantages of physical activity for lowering CVD
602260 - risk prescribed in Plan of Care for Progress Notes on 140213.
602261 - ref SDS 81 MQ5G The doctor left the examination room to consult with
602262 - Doctor Feingold, attending.
602263 -
602264 - [...below on 140519 0800 Progress Notes work plan do not
602265 - include continuing physical activity that has yielded
602266 - favorable results. ref SDS 0 OW76
602268 - ..
602269 - Doctor Alba and Doctor Feingold returned about 20 minutes later.
602270 - Doctor Feingold maintained that coronary CT angiography (CCTA) testing
602271 - with calcium score cannot be used with patient history of CABG +4
602272 - cardiothoracic surgery on 091022, ref SDS 15 PQWU, because patient
602273 - physiology was changed in a manner and to a degree that prevents
602274 - effective interpretation of radiology CT scan results. He spread his
602275 - fingers and slid both hands together signifying complexity of tangled
602276 - coronary blood vessels intertwined by surgery that overwhelms medical
602277 - analysis, suggesting finding plaques for CABG patients is like looking
602278 - for the proverbial "needle in a haystack."
602280 - ..
602281 - Controversy using CCTA radiology studies in clinical cardiology
602282 - practice to assess atherosclerosis was cited in discussions at an
602283 - international conference considering prospects for HDL to regress
602284 - plaque, reported last year On 131125. ref SDS 66 1E51
602286 - ..
602287 - [...below on 140519 0800 VA Progress Notes cite discussion
602288 - ordering coronary CTA with calcium score to test response
602289 - to treatment in order and sets out explanation that such
602290 - testing is not standard of care for patients who have had
602291 - CABG surgery because heart bypass surgery changes anatomy.
602292 - ref SDS 0 OW49
602294 - ..
602295 - [On 140529 0942 letter to VA requests progress ordering EPC
602296 - lab, and requests order for coronary CTA with calcium score
602297 - standard of care to test for response to treatment to
602298 - achieve regression of atherosclerosis. ref SDS A1 QG38
602300 - ..
602301 - [On 151019 0930 CCTA with calcium score performed;
602302 - meeting with doctor in Radiology Department reviewed
602303 - requirements for calcium score to evaluate response to
602304 - treatment recovering from atherosclorosis. ref SDS B5
602305 - GR4K At the end of the meeting, the doctor agreed to
602306 - perform calcium score for comprehensive CCTA test.
602307 - ref SDS B5 LQ5F However, analyst's report merely says
602308 - "All the bypass grafts are patent." ref SDS B5 JW8O
602310 - ..
602311 - [On 151019 0930 addendum received on 160113, and issued
602312 - by Doctor Priyanka Jha reports finding no evidence of
602313 - atherosclerosis plaque in active coronary circulatory
602314 - system, or words to that effect. ref SDS B5 QW5F
602316 - ..
602317 - [On 170412 1000 Doctor Simpson indicated that Doctor
602318 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602320 - ..
602321 - In this case, elevated coronary plaques required treatment with
602322 - surgery 5 years ago on 091022. Subsequent treatment with elevated
602323 - endurance exercise the past 3 years, and increased further the past 6
602324 - months, shown above, ref SDS 0 T64J, may have yielded rapid regression
602325 - of atherosclerotic plaques. Standard of care evaluating response to
602326 - treatment for patients with history of CABG requires testing for
602327 - elevated EPCs and ordering coronary CTA with calcium score to test
602328 - for evidence of atherosclerotic plaques...
602329 -
602330 - 1. PubMed
602332 - ..
602333 - Cardiac CT angiography after coronary bypass surgery:
602334 - prevalence of incidental findings.
602335 -
602336 - http://www.ncbi.nlm.nih.gov/pubmed/17646469
602338 - ..
602339 - 2. Journal of American College of Cardiology...
602340 -
602341 - http://imaging.onlinejacc.org/article.aspx?articleID=1879181
602343 - ..
602344 - 3. Computed Tomography Imaging in 2012
602345 -
602346 - http://books.google.ca/books?id=ASu3TUDBNCcC&pg=PA85&lpg=PA85&dq=coronary+CTA+CABG&source=bl&ots=IPn9-8gHpB&sig=iJsUE_5KAdrUjXV2kAY-Z28Rt0M&hl=en&sa=X&ei=c6asU53uBYKryATT_YGwAQ&ved=0CE8Q6AEwCA#v=onepage&q=coronary%20CTA%20CABG&f=false
602347 -
602348 - ...and saying in part...
602350 - ..
602351 - "Coronary CTA is highly accurate for the assessment of
602352 - coronary artery bypass graft (CABG) stenosis, and its use
602353 - for this purpose is endorsed by current Appropriate Use
602354 - Criteria.
602356 - ..
602357 - 4. Journal of Cardiology Cases
602358 - Volume 5, Issue 2, April 2012, Pages e92?e95
602360 - ..
602361 - Regression of coronary plaque after coronary artery bypass graft
602362 -
602363 - http://www.sciencedirect.com/science/article/pii/S1878540912000035
602364 -
602365 - ...and saying in part...
602367 - ..
602368 - Three years after treatment, 64-MDCT showed mild stenosis
602369 - and a regression of plaque in the LMT. The mean density of
602370 - the plaque was 73.1 HU (intermediate plaque) [...before
602371 - CABG and 32.4 after CABG; plaque size reduced from 20.7 to
602372 - 4.26...]
602374 - ..
602375 - Doctor Feingold seemed to say that coronary CTA tests with calcium
602376 - score are unnecessary, when there is already evidence of
602377 - atherosclerotic plaques, based on patient history of CABG surgery in
602378 - this case CABG +4 performed 5 years ago on 091022. ref SDS 15 PQWU
602379 -
602380 - [On 140626 1652 case study showing coronary CTA common
602381 - medical practice evaluate response to treatment testing for
602382 - regression atherosclerosis after CABG heart bypass surgery.
602383 - ref SDS A5 MZ54
602385 - ..
602386 - [On 141024 0900 follow up examination Doctor Rao repeated
602387 - policy position that CCTA does not yield reliable results
602388 - testing response to treatment for patients who have
602389 - undergone CABG procedure, due to surgical changes in
602390 - anatomy. ref SDS B2 S54M
602392 - ..
602393 - The doctor further seemed to say that, since atherosclerotic plaque
602394 - was found in this case 5 years ago during angiogram radiology testing
602395 - on 091021 0716, ref SDS 14 7L43, and required surgery the next day,
602396 - evidence based medical practice can now only rely on favorable lipid
602397 - testing, shown in the labs on 140508 and 140514, ref SDS 94 W25L, to
602398 - conclude atherosclerosis has not worsened. He further seemed to say
602399 - that testing for atherosclerosis after 5 years of treatment, with
602400 - coronary CTA and calcium score will not add value to current diagnosis
602401 - nor aid prescription for treatment regardless of results.
602403 - ..
602404 - No authorities, studies, published articles, nor evidence of any kind
602405 - was cited to justify failing to test for response to treatment.
602407 - ..
602408 - [...below on 140519 0800 VA Progress Notes cite discussion
602409 - ordering coronary CTA with calcium score to test response
602410 - to treatment in order and sets out explanation that such
602411 - testing is not standard of care for patients who have had
602412 - CABG surgery because heart bypass surgery changes anatomy.
602413 - ref SDS 0 OW49
602415 - ..
602416 - [On 140529 0942 letter to VA requests progress ordering EPC
602417 - lab, and requests order for coronary CTA with calcium score
602418 - standard of care to test for response to treatment to
602419 - achieve regression of atherosclerosis. ref SDS A1 QG38
602421 - ..
602422 - [On 140612 1048 letter from Doctor Alba says VA refuses to
602423 - order EPC and CTA tests to evaluate regression of
602424 - atherosclerosis because CABG surgery on 091022, changed
602425 - anatomy which renders CTA test difficult, and since
602426 - customer has history of atherosclerosis the VA will test to
602427 - evaluate whether the problem has been resolved, declined,
602428 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
602429 - by Doctor Feingold as presented in Progress Notes for
602430 - meeting at VA on 140519 0800. ref SDS 0 OW49
602432 - ..
602433 - [On 141024 0900 follow up examination Doctor Rao repeated
602434 - policy position that CCTA does not yield reliable results
602435 - testing response to treatment for patients who have
602436 - undergone CABG procedure, due to surgical changes in
602437 - anatomy. ref SDS B2 S54M
602439 - ..
602440 - [On 151019 0930 CCTA with calcium score performed;
602441 - meeting with doctor in Radiology Department reviewed
602442 - requirements for calcium score to evaluate response to
602443 - treatment recovering from atherosclorosis. ref SDS B5
602444 - GR4K At the end of the meeting, the doctor agreed to
602445 - perform calcium score for comprehensive CCTA test.
602446 - ref SDS B5 LQ5F However, analyst's report merely says
602447 - "All the bypass grafts are patent." ref SDS B5 JW8O
602449 - ..
602450 - [On 151019 0930 addendum received on 160113, and issued
602451 - by Doctor Priyanka Jha reports finding no evidence of
602452 - atherosclerosis plaque in active coronary circulatory
602453 - system, or words to that effect. ref SDS B5 QW5F
602455 - ..
602456 - [On 170412 1000 Doctor Simpson indicated that Doctor
602457 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602459 - ..
602460 - Discussed role of testing to not merely diagnose medical problems, but
602461 - also measure severity that guides treatment. Evidence based medical
602462 - practice requires testing for response to treatment. Coronary CTA
602463 - with calcium score yields results in time to make effective changes.
602464 - Standard of care increases or decreases treatments, based on favorable
602465 - or adverse test findings.
602467 - ..
602468 - [On 140626 1652 letter notifies VA of case studies showing
602469 - failure to perform timely testing causes negative patient
602470 - outcomes. ref SDS A4 MY51 VA reference to patient having
602471 - vessel plaques 5 years ago, begs the question of testing to
602472 - determine currently how much plaque, and level of care
602473 - required, if any, to treat current condition. ref SDS A4
602474 - MZ33 Evidence shows CTA common procedure to evaluate
602475 - current condition post CABG surgery. ref SDS A4 MZ54
602477 - ..
602478 - For example, Tim Russert, well known NBC television news broadcaster
602479 - died of heart attack despite LDL-C 68, indicating this common
602480 - methodology of determining low CVD risk, i.e., LDL-C < 70, is not
602481 - dispositive of atherosclerosis. As here, his doctor knew he had
602482 - plaques, but not how much. The patient finally had a coronary CTA
602483 - which yielded an atherosclerosis calcium score of 250 that should have
602484 - been 0; however, there was not enough time to adjust line of care, and
602485 - Mr Russert suffered the consequences. (see again research on 131125
602486 - line NZ0402. ref SDS 67 N73K
602488 - ..
602489 - Clearly, patients should be notified through timely test results
602490 - whether mere appearance of favorable indirect test results with lipid
602491 - labs, are contradicted by more direct testing of atherosclerosis with
602492 - coronary CTA, so that alternatives measures can be taken in time to be
602493 - effective.
602495 - ..
602496 - Doctor Feingold seemed to say that since the patient has already been
602497 - treated with available pharmacology at the VA for recovering from
602498 - atherosclerosis, nothing more can be done at the VA in the event of
602499 - adverse findings.
602500 -
602501 - [On 170412 1000 Doctor Simpson indicated that Doctor
602502 - Feingold is the resident expert on lipids. ref SDS B6 V35H
602504 - ..
602505 - We reviewed favorable clinical trials of new PCSK9 family of drugs
602506 - coming online, discussed previously with the VA reported in Progress
602507 - Notes for the meeting on 131219 0930. ref SDS 70 WF5J and ref SDS 70
602508 - E35N If the VA does not have time to provide available care with
602509 - promising results, the independent action can be taken.
602511 - ..
602512 - Doctor Alba asked that since prescribed care to maintain physical
602513 - exercise at high levels has produced highly favorable results for HDL
602514 - 67 and TG 58, shown in VA and Labcorp labs on 140514 0950, ref SDS 94
602515 - W25L, if a coronary CTA test showed favorable results, i.e., minimal
602516 - to no atherosclerosis plaque, even calcium score of 0, how would this
602517 - change prescribed care?
602518 -
602519 - [...below on 140519 0800 Doctor will discuss with
602520 - colleagues ordering coronary CTA with calcium score to test
602521 - for favorable results that support reducing prescribed care
602522 - with medication and extended endurance training, since this
602523 - would reduce difficult side effects. ref SDS 0 635O
602524 -
602525 -
602527 - ..
602528 - Atorvastatin Ezetimibe Reduce Side Effects by Reducing Dose
602529 - Side Effects Reduced by Reducing Treatment with Regression Atherosclerosis
602530 - Regression Atherosclerosis Lowers CVD Risk Reduce Treatment Reduce Side Effects
602531 -
602532 - Follow up ref SDS 81 A36K.
602533 -
602534 - Atorvastatin side effects are listed on 130603 0930. ref SDS 54 PC6O
602535 - Ezetimibe side effects are listed on 131125 0005. ref SDS 67 GD8G
602537 - ..
602538 - The letter to the VA on 140515, advised of slight dizziness over
602539 - several months taking Ezetimibe may have declined past few days.
602540 - ref SDS 95 YM98 Doctor Alba was pleased with the update report in the
602541 - letter yesterday that dizziness has entirely subsided, shown on 140518
602542 - 2120. ref SDS 96 DV50
602544 - ..
602545 - She explained that some side effects eventually go away, as the body
602546 - adjusts to new chemistry taking foreign drugs.
602548 - ..
602549 - Urination has increased, but this is hard to track. Seem to be
602550 - getting up a lot during the night, as occurred with Rosuvastatin, but
602551 - could be imagination - not sure yet, also reported on 140515.
602552 - ref SDS 95 YM98 The letter yesterday on 140518, further clarified
602553 - have had very dry mouth at night over the past week, and frequency of
602554 - urination has further increased, indicating dehydration issue.
602555 - ref SDS 96 DV56
602557 - ..
602558 - Doctor Alba advised increased urination at night could reflect
602559 - prostate issues that arise normally with aging, based on patient age
602560 - of 69. Recommends review with Primary Care.
602562 - ..
602563 - Peripheral neuropathy has begun to return, possibly related to
602564 - elevated bilirubin in the lab on 140514 0950. ref SDS 94 015M This
602565 - follows prior pattern with Rosuvastatin, but at this time the problem
602566 - is very minor, only a few occasions the past 2 weeks or so, reported
602567 - in the letter yesterday on 140518 2120. ref SDS 96 DV59 Background on
602568 - difficulties of elevated T bilirubin causing peripheral neuropathy
602569 - from taking statin drugs is reported in the record on 140514 0950.
602570 - ref SDS 94 G34G
602572 - ..
602573 - Doctor Alba related making a review of patient history that shows
602574 - elevated T bilirubin since 2009- prior to initiation of statin drugs.
602575 - She advised this indicates elevated T bilirubin may not be caused by
602576 - taking Atorvastatin.
602577 -
602578 - Collection DT T Bili Range Source
602579 - 05/08/2014 15:28 2.5 H...0.3 - 1.2.. ref SDS A7 WJ5H
602580 - 20/05/2014 10:20 1.2 ....0.3 - 1.2.. ref SDS 97 015M
602581 - 08/05/2014 11:49 1.3 H...0.0 - 1.2.. ref SDS 93 015M
602582 - 03/02/2014 09:52 2.1 H...0.3 - 1.2.. ref SDS 78 015M
602583 - 01/02/2014 12:28 1.6 H...0.0 - 1.2.. ref SDS 77 015M
602584 - 15/10/2013 08:25 1.7 H...0.3 - 1.2.. ref SDS 56 015M
602585 - 29/05/2013 08:18 1.3 H...0.3 - 1.2.. ref SDS 51 1Y9G
602586 - 28/02/2013 08:36 1.3 H...0.3 - 1.2.. ref SDS 48 6S4F
602587 - 31/08/2012 15:24 2.3 H...0.3 - 1.2.. ref SDS 35 NV9M
602588 - 09/05/2012 11:24 2.5 H...0.3 - 1.2.. ref SDS 33 O46K
602589 - 09/02/2012 11:18 1.8 H...0.3 - 1.2.. ref SDS 30 KK9M
602590 - 17/11/2011 14:27 1.3 H.............. ref SDS 28 KK9M
602591 - 13/10/2011 14:35 1.3 H.............. ref SDS 27 GM65
602592 - 27/07/2011 12:58 2.0 H.............. ref SDS 23 GM65
602593 - 07/12/2010 09:17 1.0 ............... ref SDS 22 GM65
602594 - 21/07/2010 08:54 1.3 H.............. ref SDS 18 GM65
602595 - 14/12/2009 1.3 H ............. ref DRP 1 DE4O
602596 - 02/11/2009 0.9 ............... ref DRP 1 LG4L
602597 - 13/08/2009 15:09 1.7 H.............. ref SDS 12 VG8R
602599 - ..
602600 - This record indicates T Bili high 1.7, then dropped within range at
602601 - 0.9 after heart surgery (CABG+4) on 091022.
602603 - ..
602604 - On 131017 1000 VA Cardiology Progress Notes assessment report Doctor
602605 - Egan concerned about chronic hyperbilirubinemia. ref SDS 59 PSXT
602607 - ..
602608 - Today, Doctor Alba explained this record of T Bili 2.5 over 100% above
602609 - range represents mild elevation. She advised that vigorous exercise
602610 - from hiking 300+ miles per month (see above, ref SDS 0 T64J), can
602611 - increase bilirubin levels, shown in patient history discussed during
602612 - the meeting today, per above. ref SDS 0 T64J
602614 - ..
602615 - We reviewed the record indicating that correlating elevated T Bili
602616 - with high level of physical activity for endurance training appears
602617 - conflicting with the record that peripheral neuropathy symptoms
602618 - associated with elevated T bilirubin always decline within .25 miles
602619 - or so on daily 11 mile hikes, see for example the report in case study
602620 - on 120101, for 140517. ref SDS 29 YW5F
602622 - ..
602623 - The doctor was pleased that other liver enzymes are within range.
602625 - ..
602626 - She plans to follow up on elevated bilirubin issue, but did not
602627 - elaborate.
602629 - ..
602630 - [...below on 140519 0800 VA Progress Notes confirm
602631 - understandings that patient history shows T Bili was once
602632 - elevated before starting statins; plans to follow up with
602633 - repeat lab to check liver enzymes. ref SDS 0 OW65
602635 - ..
602636 - Doctor Alba advised that side effects should not affect prescribed
602637 - care with Atorvastatin and Ezetimibe. She explained medical practice
602638 - encourages patients to tolerate inconvenient side effects of effective
602639 - treatment in order to continue benefits recovering from primary
602640 - maladies like cancer, diabetes, cardiovascular disease (CVD), etc.
602642 - ..
602643 - This conflicts with case study of Millie's care shown on 050422 1645.
602644 - ref SDS 2 OW6O On 050514, Millie stopped treatment due to side
602645 - effects of chemotherapy. ref SDS 5 RU9M On 050516, she notified
602646 - Kaiser that death would be better than continuing side effects of
602647 - capecitabine. ref SDS 6 AQ6G However, on 050520 Mil agreed to resume
602648 - treatment with reduced dose for capecitabine (Xeloda) to reduce side
602649 - effects, ref SDS 7 NT3I, because labs showed significant decline in CA
602650 - 15-3 cancer marker. ref SDS 7 GJ5M Kaiser then supplemented lab work,
602651 - with a CT test that showed her cancerous nodes had shrunk so
602652 - dramatically that the doctor advised the issue was nearly totally
602653 - resolved, reported on 050610 1545. ref SDS 8 B58M
602655 - ..
602656 - Standard of care at Kaiser testing with labs and radiology that proved
602657 - effective reducing the dose of treatment to lower side effects in
602658 - Millie's case might be applied in the current case at the VA.
602659 -
602660 -
602662 - ..
602663 - Feet Pain Metatarsalgia Podiatry Referral Regression Atherosclerosis
602664 - Podiatry Resolve Metatarsalgia Feet Pain Maintain Regression Atherosclerosis
602665 - Atherosclerosis Podiatry Resolve Metatarsalgia Feet Pain Side Effects Physical Activity
602666 -
602667 - Besides possibly increasing T Bilirubin above range that might be
602668 - causing or compounding side effects of peripheral neuropathy, noted by
602669 - Doctor Alba today, per above, ref SDS 0 U56J, endurance exercise for
602670 - regression of atherosclerosis causes other side effects that compound
602671 - degenerative arthritis in the left knee.
602673 - ..
602674 - In recent months feet have begun to hurt from reducing CVD risk
602675 - through treatment with endurance exercise hiking 300+ miles per month,
602676 - continuing physical activity prescribed on 140213. ref SDS 81 E34O
602677 - Glucosamine Chondroitin reduces joint pain from hiking this year about
602678 - 300 miles ahead of the 1st 4 months of last year, per above.
602679 - ref SDS 0 T64J
602681 - ..
602682 - Increasing metatarsalgia pain on balls of feet due to treatment with
602683 - extended hiking was reported to Doctor Egan during a meeting in
602684 - Cardiology a few weeks ago on 140430 0900. ref SDS 91 PU37, and citing
602685 - case study on 120101 0900. ref SDS 29 PS3F At that time on 140430,
602686 - Doctor Egan indicated physical activity should continue in order to
602687 - maintain benefits of lowering CVD risk. ref SDS 91 RI9N
602689 - ..
602690 - Today, Doctor Alba also feels treatment should continue in order to
602691 - maintain good results lowering CVD risks, as discussed above.
602692 - ref SDS 0 A58I
602693 -
602694 - [On 140520 0732 letter to VA Medical Center in San
602695 - Francisco cites discussion on sore feet side effects of
602696 - hiking to lower CVD risk. ref SDS 97 UT5M
602698 - ..
602699 - Since February have tried to resolve metatarsalgia side effects by
602700 - purchasing shoes with increased cushioning, and further ordered
602701 - resoling shoes to increase cushioning, since new shoe models seem to
602702 - have less cushioning, cited in a letter to Resole America last month
602703 - on 140408 1826. ref SDS 90 5L95
602705 - ..
602706 - Requested referral to Podiatry for care of metatarsalgia in order to
602707 - continue treatment hiking 300 miles per month that has yielded weight
602708 - loss, lower LDL-P and triglycerides, higher HDL and EPCs that increase
602709 - regression of atherosclerosis, thus lowering CVD risk.
602711 - ..
602712 - Doctor Alba said to remove shoes and socks.
602714 - ..
602715 - She examined both feet to assess side effects of physical activity
602716 - treating atherosclerosis toward making referral to Podiatry for
602717 - resolution of debilitating metatarsalgia side effects.
602718 -
602719 -
602721 - ..
602722 - CT Test Response Treatment Favorable Results Reduce Treatment Side Effects
602723 -
602724 - We considered standard of care to reduce side effects by testing for
602725 - response to treatment using coronary CTA with calcium score,
602726 - addressing Doctor Alba's question on why test response to treatment?
602727 - ref SDS 0 467K Favorable test results could support reducing
602728 - treatments that would in turn reduce onerous side effects of
602729 - medication, ref SDS 0 PC8K, and endurance exercise. ref SDS 0 CC8O
602731 - ..
602732 - This aligns with experience at Kaiser when Doctor Johnson reduced dose
602733 - of capecitabine chemotherapy to reduce side effects for Millie, after
602734 - testing showed that initial high dose reduced the level of detectable
602735 - cancer, reported on 050520 1045. ref SDS 7 NT3I
602737 - ..
602738 - Doctor Alba will discuss testing issue further with the VA team toward
602739 - assessing viability of reducing treatment to reduce side effects based
602740 - on evidence of improved cardiovascular health.
602741 -
602742 - [On 151019 0930 CCTA with calcium score performed;
602743 - meeting with doctor in Radiology Department reviewed
602744 - requirements for calcium score to evaluate response to
602745 - treatment recovering from atherosclorosis. ref SDS B5
602746 - GR4K At the end of the meeting, the doctor agreed to
602747 - perform calcium score for comprehensive CCTA test.
602748 - ref SDS B5 LQ5F However, analyst's report merely says
602749 - "All the bypass grafts are patent." ref SDS B5 JW8O
602751 - ..
602752 - [On 151019 0930 addendum received on 160113, and issued
602753 - by Doctor Priyanka Jha reports finding no evidence of
602754 - atherosclerosis plaque in active coronary circulatory
602755 - system, or words to that effect. ref SDS B5 QW5F
602756 -
602757 -
602758 -
602759 -
602760 -
602761 -
6028 -
SUBJECTS
Default Null Subject Account for Blank Record
6103 -
610401 - ..
610402 - Medical Chart Progress Notes Meeting 140519 VA SF Medical Center
610403 -
610404 - Follow up ref SDS 81 476K, ref SDS 70 476K.
610405 -
610406 - On 140612 VA file from CD with Progress Notes for meeting on 140519
610407 - were received through US mail from VA Medical Center in San Francisco
610408 - ROI Department for request filed on 140519. Progress Notes were
610409 - signed on 140602. ref SDS 0 QQ5K
610411 - ..
610412 - VA Progress Notes for meeting on 140519 are stored in...
610413 -
610424 - ..
610425 - Generally, these Progress Notes correct numerous errors in past
610426 - Progress Notes carried forward to notes for the last meeting on 140213
610427 - 0830, ref SDS 81 3Q3N; implements request in the letter to the VA a
610428 - week or so later on 140529 0942. ref SDS A0 QF6T
610430 - ..
610431 - 1. LOCAL TITLE: ENDOCRINE-METABOLISM CLINIC F/U (MED)
610432 - STANDARD TITLE: ENDOCRINOLOGY OUTPATITNE NOTE
610433 - DATE OF NOTE: MAY 19, 2014 @ 1300
610434 - ENTRY DATE: MAY 30, 2014 @191229
610436 - EXP COSIGNER:
610437 - URGENCY:
610438 - STATUS: COMPLETED
610444 - ..
610445 - CC: follow up for high cholesterol
610447 - ..
610448 - 2. HPI
610449 -
610450 - 1. 69 year old man with Past Medical history of CAD, s/p CABG
610451 - in 2009, Hyperlipidemia, achalasia, s/p lap heller myotomy
610452 - and fundoplication in 2009, here today for follow up for
610453 - hyperlipidemia. He was last seen in endocrine clinic
610454 - February 2014.
610456 - ..
610457 - 2. He is currently on Zetia 10 mg po daily and Atorvastatin 10
610458 - mg daily.
610460 - ..
610461 - 3. Since his last appointment he reports multiple side effects
610462 - that he thinks are related to Atorvastatin.
610463 -
610464 - 1. Report dizziness when lying down and turning head-now
610465 - improved.
610467 - ..
610468 - Report of "improved" dizziness side effects aligns with the letter
610469 - reporting dizziness subsided, and sent to the VA on 140518 2120.
610470 - ref SDS 96 DV50
610472 - ..
610473 - Progress Notes should cite authority for "patient reports" so there is
610474 - an audit trail in the record that supports patient status and care.
610476 - ..
610477 - VA Progress Notes meeting 140519 continue...
610478 -
610479 - 2. Increased urination, mostly at night.
610481 - ..
610482 - 3. Dry mouth at night.
610484 - ..
610485 - 4. Also c/o right foot discomfort that is usually last only a
610486 - couple of seconds, occurs while standing or at low speed
610487 - while hiking. He has had 2 episodes in the past couple of
610488 - weeks. Mr Welch thinks right foot discomfort is due to
610489 - neuropathy; similar to what he experienced in 2012 when he
610490 - was on Rosuvastatin.
610492 - ..
610493 - Good report generally aligns with letter to VA on 140518. Neuropathy
610494 - sensations in right foot "...last only a couple of seconds..." while
610495 - standing in line. However, when hiking this lasts about .25 miles at
610496 - current pace, which would be about 3+ minutes, and less time if pace
610497 - is increased. (see letter to VA on 140518. ref SDS 96 DV59)
610499 - ..
610500 - VA Progress Notes meeting 140519 continue...
610501 -
610502 - 4. In the past couple of months, he has increased his intake
610503 - of orange juice.
610505 - ..
610506 - This aligns with the letter to VA on 140515 2043, ref SDS 95 PQXS, and
610507 - with discussions during the meeting, shown above. ref SDS 0 4Z8I
610508 -
610509 - [On 141024 0900 Progress Notes do not mention orange
610510 - juice 750 ML per day added to diet that maintained HDL
610511 - while hiking declined. ref SDS B1 IO6J
610513 - ..
610514 - This section can be strengthened by citing quantity reported, and
610515 - correlations between orange juice quantity, 21% rise in HDL, and
610516 - clinical study results that found 21% rise in HDL reviewed on 131125
610517 - 0005. ref SDS 66 K34L
610519 - ..
610520 - VA Progress Notes meeting 140519 continue...
610521 -
610522 - 5. Also he continues with vigorous exercise- hikes in average
610523 - 11-20 miles per day a couple of times per week. Reports
610524 - weight on May 13th was 165 pounds. BMI 29.
610526 - ..
610527 - VA should report patient applied Plan prescribed for care during prior
610528 - meeting at the VA shown in Progress Notes on 140213 0830. ref SDS 81
610529 - E34O
610531 - ..
610532 - VA should cite authority for data.
610534 - ..
610535 - Hiking a "couple times per week" conflicts with the record - this past
610536 - year, hiking occurs every day of the week with 3 - 4 days off per
610537 - month, averaging 300 miles per month, shown in case study on
610538 - medication, diet, vitals and exercise in the record on 120101 0900.
610539 - ref SDS 29 7718 This data is presented in lab reports on 140514,
610540 - which was referenced with electronic links in a letter on 140515 2043.
610541 - ref SDS 95 YM82
610542 -
610543 - [On 140629 1921 follow up letter to VA on 140520, ordering
610544 - coronary CTA with calcium score, ref SDS 97 VQ48, to assess
610545 - reducing level of care hiking 11 miles per day in order to
610546 - reduce side effects, ref SDS A6 UZ64; further request
610547 - referral to Podiatry for consultation to relieve
610548 - metatarsalgia side effects of prescribed care. ref SDS A6
610549 - U14H
610551 - ..
610552 - Weight reported on 140513 was 163, see case study. ref SDS 29 ZU5G
610554 - ..
610555 - This data was submitted to the VA in a letter on 140515 2043.
610556 - ref SDS 95 YM82
610558 - ..
610559 - Hiking mileage is also shown to reconcile improved labs in the record
610560 - on 140514 0950. ref SDS 94 I17G
610562 - ..
610563 - VA Progress Notes meeting 140519 continue...
610564 -
610565 - 6. Most recent labs at Labcorp and VA system showed a LDL
610566 - 87-83 HDL 66-67.
610568 - ..
610569 - 7. Mr Welch also reports recent labs that showed elevated potassium,
610570 - as well as elevated total bilirubin. His cardiologist brought up
610571 - these issues. Since May 2013 Potassium has ranged between
610572 - 4. -5.6 and T Bil between 1.3-2.1 [normal direct bilirubin]. Mr
610573 - Welch is concerned that this could be secondary to Atorvastatin.
610574 - His cardiologist also considered that dehydration and vigorous
610575 - exercise could be the cause of hyperkalemia and mildly elevated
610576 - bilirubin. Of note, review of records shows a total bilirubin of
610577 - 3.0 in October 2009- prior to initiation of statins.
610579 - ..
610580 - Curious VA does not present addendum reporting results of chem lab
610581 - ordered by Doctor Alba to evaluate dehydration theory, and reported on
610582 - 140520 0732. ref SDS 97 KK9M
610584 - ..
610585 - Citing "total bilirubin of 3.0 in October 2009 is not helpful, since
610586 - there were many labs - actually everyday post CABG on 091022. The
610587 - record on CABG was received from the VA on 100928 0706. ref SDS 19
610588 - PG5M
610589 -
610590 - Collection DT T Bili Range Source
610591 - 02/09/2012 11:18 1.8 H...0.3 - 1.2.. ref SDS 30 KK9M
610592 - 11/17/2011 14:27 1.3 H.............. ref SDS 28 KK9M
610593 - 10/13/2011 14:35 1.3 H.............. ref SDS 27 GM65
610594 - 07/27/2011 12:58 2.0 H.............. ref SDS 23 GM65
610595 - 12/07/2010 09:17 1.0 ............... ref SDS 22 GM65
610596 - 07/21/2010 08:54 1.3 H.............. ref SDS 18 GM65
610597 - 08/13/2009 15:09 1.7 H.............. ref SDS 12 VG8R
610598 - 11/02/2009 0.9 ............... ref DRP 1 LG4L
610599 - 12/14/2009 1.3 H ............. ref DRP 1 DE4O
610601 - ..
610602 - Cannot find lab with bilirubin 3.0 nor VA lab in October 2009?
610604 - ..
610605 - VA Progress Notes meeting 140519 continue...
610606 -
610607 - 3. Pertinent history.
610608 -
610609 - 1. Patient was started on Simvastatin approximately 2-3 years
610610 - ago, LDL at that time was around 180's - reports that his
610611 - LDL dropped to 96 while on simvastatin, however he reports
610612 - he develop "left shoulder myopathy"- he described pain on
610613 - his left shoulder and inability to raise it above 90
610614 - degrees- No CPK on records.
610616 - ..
610617 - 2. He was then started on Rosuvastatin 10 mg po daily and report
610618 - that his LDL improved. Rosuvastatin was then increased to 20 mg
610619 - and he developed sexual dysfunction, dizziness, dry mouth and
610620 - right foot numbness.
610622 - ..
610623 - 3. As per cardiology notes in September 2012- Rosuvastatin was
610624 - decreased to 10mg po daily and dizziness improved, but he
610625 - continued to complain of right foot numbness.
610627 - ..
610628 - 4. He now has he has been off the Rosuvastatin since 12/2012,
610629 - and he continues to complain of right foot numbness, but he
610630 - reports less episodes of right sole numbness with decreased
610631 - intensity. Of note, he was seen by neurology February 2013
610632 - for the foot numbness, Vit B12 level was within normal
610633 - range, fasting glucose level ranges from 108 to 115 mg/dl,
610634 - Hga1c 5.5 October 2013; as per neurology notes no evidence
610635 - of radiculopathy or neuropathy.
610637 - ..
610638 - 4. Past Medical, Surgical, social and family history reviewed an
610639 - unchanged
610641 - ..
610642 - This note reflects entry in Progress Notes para 4, PSH, for meeting at
610643 - VA on 131121 0930. ref SDS 64 W49F
610645 - ..
610646 - Patient Medical History is shown in Progress Notes for meeting with
610647 - Doctor Egan in Cardiology on 140430 0900. ref SDS 91 TX50
610649 - ..
610650 - VA Progress Notes meeting 140519 continue...
610651 -
610652 - 5. ROS- see above
610654 - ..
610655 - 6. MEDICATIONS:
610656 - Omeprazole 20 mg BID
610657 - Atorvastatin 10 mg po daily
610658 - Zetia 10 mg po daily
610660 - ..
610661 - 7. PHYSICAL EXAM
610662 - VS
610663 - HT: 66 in [167.6 cm] (12/16/2009 18:00)
610664 - WT: 187.2 lb [85.1 kg] (05/19/2014 08:07)
610665 - HR: 61 (05/19/2014 08:07)
610666 - BP: 115/68 (05/19/2014 08:07)
610667 - Temp: 97.1 F [36.2 C] (12/20/2009 08:46)
610668 - RR: 18 (02/13/2014 08:19)
610669 - O2 Sat: 5/19/14 08:07:12 O297
610670 - BMI: 30.3 (Obesity Level I)
610672 - ..
610673 - 8. PE
610674 - Gen : NAD, AAO x3
610675 - HEENT : NC/AT, MMM, PERRL.
610676 - Neck : supple.
610677 - CARDIO : RRR, no murmurs appreciated
610678 - LUNGS : CTA Bl, no wheezes, no rales
610679 - EXT : no edema, no cyanosis, no xanthemas.Normal sensations. +
610680 - onychomychosis in bilateral feet. Normal sensation.
610682 - ..
610683 - 9. LABS:
610684 - May 14 2014
610685 - 05/14/2014 CHOLESTEROL 164.00 100 - 240 PLASMA
610686 - 05/14/2014 TRIGLYCERIDE 58.00 10 - 190 PLASMA
610687 - 05/14/2014 HDL 66.00 35 - PLASMA
610688 - 05/14/2014 LDL CHOL(Calculated 87.00 - 131 PLASMA
610689 - 05/14/2014 HEMOGLOBIN A1C 5.40 4.0 - 6.0 SERUM
610691 - ..
610692 - 10. PLASMA ALB TP
610693 - [c] May 14, 2014 10:16 4.6 7.5
610695 - ..
610696 - 11. PLASMA ALKP SGOT SGPT
610697 - [c] May 14, 2014 10:16 93 33 27
610698 -
610699 - 12. ********************************************************
610701 - ..
610702 - 13. PLASMA T BIL D BIL
610703 - [c] May 14, 2014 10:16 2.2 H 0.2
610705 - ..
610706 - 14. VA System
610707 - May 8 2014 TC 162 LDL 83 HDL 67 TG 59
610708 - Feb 3rd 2014 TC 160 LDL 93 HDL 58 TG 47 HgA1c 5.5%
610709 - Labcorp TC 156 LDL 81 HDL 61 TG 61
610711 - ..
610712 - 15. October 2013 TC 321 LDL 249 HLD 50 TG 85 TBil 1.7
610713 - Hga1c 5.5% CPK 110 TSH 2.6
610715 - ..
610716 - 16. May 2013 TC 307 LDL 240 HLD 54 TG 85 TBil 1.3
610717 - November 2012 TC 173 LDL 105 HLD 57 TG 53 TBil 1.6
610718 -
610720 - ..
610721 - 17. Assessment and Plan:
610722 -
610723 - 18. 69 year old male with history of CAD, s/p CABG in 2009,
610724 - Hyperlipidemia, referred by cardiology for management of
610725 - hyperlipidemia. Here today for follow up.
610727 - ..
610728 - 19. Again improved LDL on Atorvastatin 10 mg po daily and Zetia 10 mg
610729 - daily, although still not at goal on a patient with known
610730 - coronary artery disease and CABG. LDL goal is less than 70mg/dL.
610731 - Explained to Mr Welch that although diet and exercise are
610732 - important lifestyle changes in the management of hyperlipidemia,
610733 - he needs to continue current regimen to achieve LDL goal.
610735 - ..
610736 - VA Progress Notes saying "...LDL is still not at goal," appears
610737 - conflicting with VA lab on 140514, finding LDL-C 87, and Labcorp blood
610738 - test on 140508, shows LDL-C 83, well below VA published "goal" <= 130,
610739 - and Labcorp "goal" < 100, all shown in consolidated results on 140514
610740 - 0950. ref SDS 94 W25L Recent guidance published by American Heart
610741 - Association - AHA - shows LDL-C "goal" < 190, reported on 131112 1422.
610742 - ref SDS 61 HT87
610743 -
610744 - [On 141106 0630 make-up lipid blood test reported LDL-C 67,
610745 - which aligns with VA "goal" for LDL-C < 70, ref SDS B4
610746 - U45J; however, it results from 20 unit deline in total
610747 - cholesterol from 156 to 137 over just 2 weeks, and so
610748 - conflicts with patient history of stable cholesterol for
610749 - prior 12 months. ref SDS B4 W25L
610751 - ..
610752 - VA should submit authority for LDL goal < 70 - presenting medical
610753 - analysis, study, etc., that justifies "goal" of LDL-C < 70?
610755 - ..
610756 - Since LDL-P 851 was reported on Labcorp NMR test 140508, and since
610757 - Labcorp guidance says LDL-P <1000 is the best lipid condition for
610758 - cardio vascular health shown in consolidated labs on 140514 0950,
610759 - ref SDS 94 BE6O, and since VA Progress Notes say LDL-P has stronger
610760 - association with CVD risk than LDL-C, reported on 131219 0930,
610761 - ref SDS 70 GO35, then why are LDL-P results not reported in Progress
610762 - Notes showing alignment with "goal" to lower CVD risk?
610764 - ..
610765 - VA Progress Notes meeting 140519 continue...
610766 -
610767 - 20. Mr Welch inquired about medical trials for PCSK9 ab. At this
610768 - time, there are no clinical trials at SF VA involving PCSK9.
610769 - Patient was provided with information regarding clinical trials
610770 - in the bay area, in December 2013.
610772 - ..
610773 - 21. Mr Welch also expressed interest in CTA to assess regression of
610774 - atherosclerotic plaques. Dr Feingold explained to Mr welch that
610775 - CTA is not used in patients that have already had CABG, since the
610776 - anatomy has changed, and in his case we know that the many of his
610777 - coronaries have plaques and calcifications- that being the reason
610778 - he needed to undergo coronary artery bypass grafting in 2009.
610780 - ..
610781 - This aligns with discussion during the meeting this morning, where
610782 - Doctor Feingold intertwined his fingers to illustrate tangled changes
610783 - to anatomy from CABG surgery, which he maintained prevented analysing
610784 - atherosclerotic plaques in coronary blood vessels, per above.
610785 - ref SDS 0 J83H For some reason, Progress Notes omit research showing
610786 - coronary CTA with calcium score is standard of care to test response
610787 - to treatment for regression of atherosclerosis, per above. ref SDS 0
610788 - OF7N
610790 - ..
610791 - [On 151019 0930 CCTA with calcium score performed;
610792 - meeting with doctor in Radiology Department reviewed
610793 - requirements for calcium score to evaluate response to
610794 - treatment recovering from atherosclorosis. ref SDS B5
610795 - GR4K At the end of the meeting, the doctor agreed to
610796 - perform calcium score for comprehensive CCTA test.
610797 - ref SDS B5 LQ5F However, analyst's report merely says
610798 - "All the bypass grafts are patent." ref SDS B5 JW8O
610800 - ..
610801 - [On 151019 0930 addendum received on 160113, and issued
610802 - by Doctor Priyanka Jha reports finding no evidence of
610803 - atherosclerosis plaque in active coronary circulatory
610804 - system, or words to that effect. ref SDS B5 QW5F
610806 - ..
610807 - During the meeting today, Doctor Alba and Doctor Feingold further
610808 - maintained that coronary CTA with calcium score is not standard of
610809 - care to test for regression of atherosclerosis because knowing the
610810 - severity of atherosclerosis plaques will not add any value to current
610811 - diagnoses or treatment, per above. ref SDS 0 M16K
610813 - ..
610814 - Controversy using CCTA radiology studies in clinical cardiology
610815 - practice to assess atherosclerosis was cited in discussions at an
610816 - international conference considering prospects for HDL to regress
610817 - plaque, reported last year On 131125. ref SDS 66 1E51
610818 -
610819 - [On 141009 0900 ad hoc discussion - doctor in VA Cardiology
610820 - Department used very similar language to discourage
610821 - customers seeking coronary CTA with calcium score to test
610822 - for response to treatment recovering from atherosclerosis
610823 - and for the purpose of lowering risk of CVD. ref SDS A9
610824 - AK6K
610826 - ..
610827 - These Progress Notes do not present discussions during the meeting
610828 - that testing to disclose severe atherosclerosis provides opportunity
610829 - to adjust treatment in time to be effective, citing well known case of
610830 - Tim Russert. ref SDS 0 6W3M The notes do not set out representations
610831 - to the effect that alternative treatments are not available at the VA,
610832 - nor that patients are entitled to the opportunity to seek alternative
610833 - treatment, if needed, including clinical trials with PCSK9 drugs, per
610834 - above. ref SDS 0 6P4I
610836 - ..
610837 - Progress Notes further omit discussion of opportunity to reduce
610838 - treatment in order to reduce both cost and severe side effects in the
610839 - event testing finds significant regression of atherosclerosis, per
610840 - above. ref SDS 0 635O
610841 -
610842 - [On 140529 0942 letter to VA requests progress ordering EPC
610843 - lab, and requests order for coronary CTA with calcium score
610844 - standard of care to test for response to treatment to
610845 - achieve regression of atherosclerosis. ref SDS A1 QG38
610847 - ..
610848 - [On 140612 1048 letter from Doctor Alba says VA refuses to
610849 - order EPC and CTA tests to evaluate regression of
610850 - atherosclerosis because CABG surgery on 091022, changed
610851 - anatomy which renders CTA test difficult, and since
610852 - customer has history of atherosclerosis the VA will test to
610853 - evaluate whether the problem has been resolved, declined,
610854 - unchanged or worsened, ref SDS A2 X45G, reflecting remarks
610855 - by Doctor Feingold as presented in Progress Notes for
610856 - meeting at VA on 140519 0800. ref SDS 0 OW49
610858 - ..
610859 - [On 140626 1652 letter notifies VA of case studies showing
610860 - failure to perform timely testing causes negative patient
610861 - outcomes. ref SDS A4 MY51 VA reference to patient having
610862 - vessel plaques 5 years ago, begs the question of testing to
610863 - determine currently how much plaque, and level of care
610864 - required, if any, to treat current condition. ref SDS A4
610865 - MZ33 Evidence shows CTA common procedure to evaluate
610866 - current condition post CABG surgery. ref SDS A4 MZ54
610868 - ..
610869 - VA Progress Notes meeting 140519 continue...
610870 -
610871 - 22. Regarding elevated potassium, this could be secondary to vigorous
610872 - exercise, since potassium can be released from active muscle
610873 - cells. No reports of statin causing hyperkalemia. Will plan to
610874 - repeat potassium levels. Instructed Mr Welch to repeat labs on a
610875 - day that he is appropriately hydrated and avoid hiking the day
610876 - prior to lab tests.
610878 - ..
610879 - 23. Review of records showed elevated total bilirubin [ with normal
610880 - direct bilirubin levels] since 2009- prior to initiation of
610881 - statins. Most likely mild elevation of unconjugated bilirubin is
610882 - secondary to Gilbert's syndrome. Gilberts' syndrome is a
610883 - phenotypic defect that causes increase in unconjugated bilirubin
610884 - under conditions of exertion, stress, fasting or infection and is
610885 - usually asymptomatic. Also vigorous exercise can increase
610886 - bilirubin levels due to destruction of red blood cells. All
610887 - other liver enzymes are within normal limits. Will follow up.
610889 - ..
610890 - This analysis aligns with understandings during the meeting with
610891 - Doctor Alba finding patient history shows 1 slightly elevated
610892 - potassium lab in 2009 prior to CABG, which then declined, but
610893 - increased markedly over next few years with prescription of statins
610894 - and increased dosage, possibly reflecting progressive injury to liver.
610895 - per above. ref SDS 0 UI3F
610897 - ..
610898 - VA Progress Notes meeting 140519 continue...
610899 -
610900 - 24. Plan
610901 -
610902 - 1. Continue Atorvastatin 10 mg po daily and Zetia 10 mg po daily.
610903 -
610904 - 2. Weight reduction- Current BMI of 29. Encourage low fat/low
610905 - carbohydrate diet.
610907 - ..
610908 - Progress Notes for prior meeting on 140213 presented a Plan - "Weight
610909 - stable, continue physical activity and low fat/low cholesterol diet."
610910 - ref SDS 81 E34O During the meeting today, the doctor credited
610911 - effective implementation of the prior plan for physical activity, per
610912 - above, ref SDS 0 K77I, based on hiking 300+ miles per month, also
610913 - above. ref SDS 0 T64J Doctor citing elevated BMI of 29, appears
610914 - conflicting with Progress Notes work plan today failing to continue
610915 - prior prescription for physical activity that yields weight loss,
610916 - favorable lipid profile, and regression of atherosclerosis that
610917 - reduces CVD risk.
610919 - ..
610920 - VA Progress Notes meeting 140519 continue...
610921 -
610922 - 3. Follow up Lipid panel in 4 months prior to next appointment.
610923 -
610924 - 4. Will repeat potassium and liver enzymes levels in 1 weeks.
610926 - ..
610927 - 25. Patient was seen and discussed with Dr Feingold
610929 - ..
610930 - 26. Clinical Reminder Activity
610932 - ..
610933 - 27. MED REC NON PRIMARY CARE:
610935 - ..
610936 - 28. Medication Reconciliation completed, including non-VA
610937 - medications and discrepancies, if identified, were
610938 - addressed.
610940 - ..
610941 - 29. Medication, medication changes and importance of medication
610942 - management were reviewed with the patient/caregiver. An
610943 - updated list of reconciled medications has been provided to
610944 - the patient/caregiver.
610946 - ..
610947 - 30. /es/ DIANA ALBA, MD
610948 - Endocrinology Fellow
610949 - Signed: 06/02/2014 07:20
610950 -
610951 -
610952 -
610953 -
610954 -
610955 -
610956 -
610957 -
610958 -
610959 -
610960 -
610961 -
610962 -
610963 -
610964 -
610965 -
610966 -
610967 -
610968 -
610969 -
610970 -
610971 -
610972 -
6110 -